113 related articles for article (PubMed ID: 22446296)
1. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients.
Tuettenberg J; Seiz M; Debatin KM; Hollburg W; von Staden M; Thiemann M; Hareng B; Fricke H; Kunz C
Int Immunopharmacol; 2012 May; 13(1):93-100. PubMed ID: 22446296
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.
Blaes J; Thomé CM; Pfenning PN; Rübmann P; Sahm F; Wick A; Bunse T; Schmenger T; Sykora J; von Deimling A; Wiestler B; Merz C; Jugold M; Haberkorn U; Abdollahi A; Debus J; Gieffers C; Kunz C; Bendszus M; Kluge M; Platten M; Fricke H; Wick W; Lemke D
Mol Cancer Res; 2018 May; 16(5):767-776. PubMed ID: 29453321
[TBL] [Abstract][Full Text] [Related]
3. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma.
Wick W; Fricke H; Junge K; Kobyakov G; Martens T; Heese O; Wiestler B; Schliesser MG; von Deimling A; Pichler J; Vetlova E; Harting I; Debus J; Hartmann C; Kunz C; Platten M; Bendszus M; Combs SE
Clin Cancer Res; 2014 Dec; 20(24):6304-13. PubMed ID: 25338498
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.
Boch T; Luft T; Metzgeroth G; Mossner M; Jann JC; Nowak D; Meir F; Schumann C; Klemmer J; Brendel S; Fricke H; Kunz C; Weiß C; Hofmann WK; Nolte F
Leuk Res; 2018 May; 68():62-69. PubMed ID: 29549809
[TBL] [Abstract][Full Text] [Related]
5. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
[TBL] [Abstract][Full Text] [Related]
6. APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.
Raimbault A; Pierre-Eugene C; Rouquette A; Deudon C; Willems L; Chapuis N; Mathis S; Kunz C; Fricke H; Kosmider O; Bardet V; Fontenay M;
Oncotarget; 2016 Mar; 7(12):14898-911. PubMed ID: 26910909
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis.
Chen X; Hou Y; Jiang J; Zhao Q; Zhong W; Wang W; Yao X; Li L; Fang J; Zhang F; Hu P
Clin Pharmacokinet; 2014 Nov; 53(11):1033-44. PubMed ID: 25179916
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
9. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT-18 in Chinese Patients With Systemic Lupus Erythematosus.
Zhao Q; Chen X; Hou Y; Jiang J; Zhong W; Yao X; Wang W; Li L; Fang J; Zhang F; Hu P
J Clin Pharmacol; 2016 Aug; 56(8):948-59. PubMed ID: 26634642
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.
Rosario M; Wyant T; Leach T; Sankoh S; Scholz C; Parikh A; Fox I; Feagan BG
Clin Drug Investig; 2016 Nov; 36(11):913-923. PubMed ID: 27422740
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Wen PY; Omuro A; Ahluwalia MS; Fathallah-Shaykh HM; Mohile N; Lager JJ; Laird AD; Tang J; Jiang J; Egile C; Cloughesy TF
Neuro Oncol; 2015 Sep; 17(9):1275-83. PubMed ID: 26019185
[TBL] [Abstract][Full Text] [Related]
13. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.
Barrington P; Chien JY; Tibaldi F; Showalter HD; Schneck K; Ellis B
Diabetes Obes Metab; 2011 May; 13(5):434-8. PubMed ID: 21251179
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
Rosenberg G; Angel I; Kozak A
Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
[TBL] [Abstract][Full Text] [Related]
15. A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants.
Lim CN; Kantaridis C; Huyghe I; Gorman D; Berasi S; Sonnenberg GE
Pharmacol Res Perspect; 2021 Aug; 9(4):e00813. PubMed ID: 34369667
[TBL] [Abstract][Full Text] [Related]
16. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
Moreland LW; Baumgartner SW; Schiff MH; Tindall EA; Fleischmann RM; Weaver AL; Ettlinger RE; Cohen S; Koopman WJ; Mohler K; Widmer MB; Blosch CM
N Engl J Med; 1997 Jul; 337(3):141-7. PubMed ID: 9219699
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.
Kretsos K; Golor G; Jullion A; Hickling M; McCabe S; Shaw S; Jose J; Oliver R
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):388-95. PubMed ID: 27129012
[TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
[TBL] [Abstract][Full Text] [Related]
19. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
Du Bois JS; Trehu EG; Mier JW; Shapiro L; Epstein M; Klempner M; Dinarello C; Kappler K; Ronayne L; Rand W; Atkins MB
J Clin Oncol; 1997 Mar; 15(3):1052-62. PubMed ID: 9060545
[TBL] [Abstract][Full Text] [Related]
20. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]